Bart O Roep

List of Publications by Year
in descending order

148 papers	11,086 citations	31976 53 h-index	32842 100 g-index
186 all docs	186 docs citations	186 times ranked	8817 citing authors

#	Article	IF	Citations
1	Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients. American Journal of Transplantation, 2022, 22, 927-936.	4.7	10
2	Improving the Prediction of Type 1 Diabetes Across Ancestries. Diabetes Care, 2022, 45, e48-e50.	8.6	7
3	Congenital beta cell defects are not associated with markers of islet autoimmunity, even in the context of high genetic risk for type 1 diabetes. Diabetologia, 2022, , 1.	6.3	1
4	Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes. Frontiers in Immunology, 2022, 13, .	4.8	9
5	A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia, 2021, 64, 313-324.	6.3	27
6	Type 1 diabetes mellitus as a disease of the Î²-cell (do not blame the immune system?). Nature Reviews Endocrinology, 2021, 17, 150-161.	9.6	256
7	Image-Based Machine Learning Algorithms for Disease Characterization in the Human Type 1 Diabetes Pancreas. American Journal of Pathology, 2021, 191, 454-462.	3.8	19
8	Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut, 2021, 70, 92-105.	12.1	161
9	1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic tolerogenic dendritic cells with specific epigenetic modifications. Cytotherapy, 2021, 23, 242-255.	0.7	12
10	Islet-Resident Dendritic Cells and Macrophages in Type 1 Diabetes: In Search of Bigfootâ€™s Print. Frontiers in Endocrinology, 2021, 12, 666795.	3.5	19
11	GPA33 is expressed on multiple human blood cell types and distinguishes CD4⁺ central memory T cells with and without effector function. European Journal of Immunology, 2021, 51, 1377-1389.	2.9	1
12	Breaking and restoring immune tolerance to pancreatic beta-cells in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, Publish Ahead of Print, 397-403.	2.3	12
13	Long RNA Sequencing and Ribosome Profiling of Inflamed Î²-Cells Reveal an Extensive Translatome Landscape. Diabetes, 2021, 70, 2299-2312.	0.6	10
14	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. , 2021, 9, e002627.		15
15	Defining a cure for type 1 diabetes: a call to action. Lancet Diabetes and Endocrinology,the, 2021, 9, 553-555.	11.4	12
16	Syntaxin 4 enrichment in Î²-cells prevents conversion to autoimmune diabetes in non-obese diabetic (NOD) mice. Diabetes, 2021, 70, db210170.	0.6	3
17	Human islet T cells are highly reactive to preproinsulin in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	42
18	Chronic marijuana usage by human pancreas donors is associated with impaired islet function. PLoS ONE, 2021, 16, e0258434.	2.5	1

#	Article	IF	Citations
19	Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. Diabetologia, 2020, 63, 597-610.	6.3	60
20	Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetes. Diabetologia, 2020, 63, 351-361.	6.3	22
21	Multidimensional analyses of proinsulin peptide-specific regulatory T cells induced by tolerogenic dendritic cells. Journal of Autoimmunity, 2020, 107, 102361.	6.5	7
22	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care, 2020, 43, 5-12.	8.6	220
23	Negative selection of human T cells recognizing a naturally-expressed tissue-restricted antigen in the human thymus. Journal of Translational Autoimmunity, 2020, 3, 100061.	4.0	9
24	Improving Clinical Islet Transplantation Outcomes. Diabetes Care, 2020, 43, 698-700.	8.6	8
25	Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptideâ€"for type 1 diabetes. Lancet Diabetes and Endocrinology,the, 2020, 8, 470-472.	11.4	55
26	Antiâ€"PD-1 Therapyâ€"Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma. Diabetes Care, 2020, 43, 2293-2295.	8.6	19
27	Î²-Cell Stress Shapes CTL Immune Recognition of Preproinsulin Signal Peptide by Posttranscriptional Regulation of Endoplasmic Reticulum Aminopeptidase 1. Diabetes, 2020, 69, 670-680.	0.6	29
28	There Is Something About Insulin Granules. Diabetes, 2020, 69, 2575-2577.	0.6	2
29	Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances. Diabetes, 2019, 68, 1366-1379.	0.6	49
30	Activated Mesenchymal Stromal Cells Process and Present Antigens Regulating Adaptive Immunity. Frontiers in Immunology, 2019, 10, 694.	4.8	53
31	Conjugation of a peptide autoantigen to gold nanoparticles for intradermally administered antigen specific immunotherapy. International Journal of Pharmaceutics, 2019, 562, 303-312.	5.2	44
32	Persistent Câ€peptide is associated with reduced hypoglycaemia but not HbA_{1c} in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabetic Medicine, 2019, 36, 1092-1099.	2.3	32
33	Diabetes relief in mice by glucose-sensing insulin-secreting human Î±-cells. Nature, 2019, 567, 43-48.	27.8	188
34	Intra-pancreatic tissue-derived mesenchymal stromal cells: a promising therapeutic potential with anti-inflammatory and pro-angiogenic profiles. Stem Cell Research and Therapy, 2019, 10, 322.	5.5	7
35	A viral link for type 1 diabetes. Nature Medicine, 2019, 25, 1816-1818.	30.7	9
36	Islet Allotransplantation in the Bone Marrow of Patients With Type 1 Diabetes: A Pilot Randomized Trial. Transplantation, 2019, 103, 839-851.	1.0	27

#	Article	IF	Citations
37	Vitamin D controls the capacity of human dendritic cells to induce functional regulatory T cells by regulation of glucose metabolism. Journal of Steroid Biochemistry and Molecular Biology, 2019, 187, 134-145.	2.5	71
38	Epitope Stealing as a Mechanism of Dominant Protection by HLA-DQ6 in Type 1 Diabetes. Diabetes, 2019, 68, 787-795.	0.6	20
39	Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabetes and Endocrinology,the, 2019, 7, 65-74.	11.4	102
40	The challenge of modulating Î²-cell autoimmunity in type 1 diabetes. Lancet Diabetes and Endocrinology,the, 2019, 7, 52-64.	11.4	124
41	Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. European Journal of Endocrinology, 2019, 181, 363-374.	3.7	154
42	Abnormal islet sphingolipid metabolism in type 1 diabetes. Diabetologia, 2018, 61, 1650-1661.	6.3	56
43	SLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipients. Diabetologia, 2018, 61, 1623-1632.	6.3	1
44	Combinatorial detection of autoreactive CD8+ T cells with HLA-A2 multimers: a multi-centre study by the Immunology of Diabetes Society T Cell Workshop. Diabetologia, 2018, 61, 658-670.	6.3	22
45	Bioluminescent reporter assay for monitoring ER stress in human beta cells. Scientific Reports, 2018, 8, 17738.	3.3	10
46	Association between maternal gluten intake and type 1 diabetes in offspring: national prospective cohort study in Denmark. BMJ: British Medical Journal, 2018, 362, k3547.	2.3	41
47	Islet stress, degradation and autoimmunity. Diabetes, Obesity and Metabolism, 2018, 20, 88-94.	4.4	43
48	Syntaxin 4 Expression in Pancreatic Î²-Cells Promotes Islet Function and Protects Functional Î²-Cell Mass. Diabetes, 2018, 67, 2626-2639.	0.6	14
49	Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells. Transplantation, 2018, 102, 1223-1229.	1.0	72
50	A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes. Frontiers in Immunology, 2018, 9, 690.	4.8	12
51	Heterogeneity of circulating CD8 T-cells specific to islet, neo-antigen and virus in patients with type 1 diabetes mellitus. PLoS ONE, 2018, 13, e0200818.	2.5	38
52	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. Diabetes Care, 2018, 41, 1486-1492.	8.6	81
53	Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nature Medicine, 2017, 23, 501-507.	30.7	182
54	The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes. Diabetologia, 2017, 60, 1185-1189.	6.3	32

#	Article	IF	Citations
55	Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. Diabetes, 2017, 66, 722-734.	0.6	154
56	Relapsing/remitting type 1 diabetes. Diabetologia, 2017, 60, 2252-2255.	6.3	12
57	Type 1 diabetes induction in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10954-10959.	7.1	67
58	Understanding and preventing type 1 diabetes through the unique working model of TrialNet. Diabetologia, 2017, 60, 2139-2147.	6.3	59
59	Immunogenicity of human embryonic stem cell-derived beta cells. Diabetologia, 2017, 60, 126-133.	6.3	49
60	Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes. Frontiers in Immunology, 2017, 8, 167.	4.8	65
61	Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials. Frontiers in Immunology, 2017, 8, 1598.	4.8	32
62	Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study. PLoS ONE, 2017, 12, e0188475.	2.5	163
63	Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 Diabetes. PLoS ONE, 2016, 11, e0146649.	2.5	12
64	HLA-A*24Carrier Status and Autoantibody Surges Posttransplantation Associate With Poor Functional Outcome in Recipients of an Islet Allograft. Diabetes Care, 2016, 39, 1060-1064.	8.6	11
65	Where, How, and When: Positioning Posttranslational Modification Within Type 1 Diabetes Pathogenesis. Current Diabetes Reports, 2016, 16, 63.	4.2	26
66	Neoantigens and Microenvironment in Type 1 Diabetes: Lessons from Antitumor Immunity. Trends in Endocrinology and Metabolism, 2016, 27, 353-362.	7.1	22
67	Insulitis Revisited. Diabetes, 2016, 65, 545-547.	0.6	1
68	A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes. Current Opinion in Immunology, 2016, 43, 67-73.	5.5	40
69	Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes. Genes and Immunity, 2016, 17, 342-348.	4.1	32
70	Human islets and dendritic cells generate post-translationally modified islet autoantigens. Clinical and Experimental Immunology, 2016, 185, 133-140.	2.6	38
71	Variation in the CTLA4 3â€²UTR has phenotypic consequences for autoreactive T cells and associates with genetic risk for type 1 diabetes. Genes and Immunity, 2016, 17, 75-78.	4.1	26
72	Dendritic Cells Guide Islet Autoimmunity through a Restricted and Uniquely Processed Peptidome Presented by High-Risk HLA-DR. Journal of Immunology, 2016, 196, 3253-3263.	0.8	24

#	Article	IF	Citations
73	Discovery of a Selective Islet Peptidome Presented by the Highest-Risk HLA-DQ8trans Molecule. Diabetes, 2016, 65, 732-741.	0.6	35
74	Multiple autoantibodies at onset do not accurately predict long-term pancreatic beta-cell fate in a 13-year-old obese child with immediate insulin-requiring diabetes. Diabetes and Metabolism, 2016, 42, 69-70.	2.9	2
75	Vitamin D receptor polymorphisms and growth until adulthood after very premature birth. Journal of Bone and Mineral Metabolism, 2016, 34, 564-570.	2.7	1
76	Innate and adaptive immunity to human beta cell lines: implications for beta cell therapy. Diabetologia, 2016, 59, 170-175.	6.3	19
77	Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clinical and Experimental Immunology, 2015, 182, 251-260.	2.6	52
78	Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97. PLoS ONE, 2015, 10, e0128206.	2.5	27
79	Primary prevention for type 1 diabetes mellitus?. Nature Reviews Endocrinology, 2015, 11, 451-452.	9.6	2
80	Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray. Immunotherapy, 2015, 7, 163-174.	2.0	30
81	T cell receptor reversed polarity recognition of a self-antigen major histocompatibility complex. Nature Immunology, 2015, 16, 1153-1161.	14.5	115
82	Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells. Clinical and Experimental Rheumatology, 2015, 33, S97-103.	0.8	24
83	Posttranslational Modification of HLA-DQ Binding Islet Autoantigens in Type 1 Diabetes. Diabetes, 2014, 63, 237-247.	0.6	150
84	Immune modulation in humans: implications for type 1 diabetes mellitus. Nature Reviews Endocrinology, 2014, 10, 229-242.	9.6	121
85	Immune intervention therapy in type 1 diabetes: safety first. Lancet Diabetes and Endocrinology,the, 2013, 1, 263-265.	11.4	3
86	Î²-Cells, Autoimmunity, and the Innate Immune System: â€œun MÃ©nage Ã¡ Troisâ€?. Diabetes, 2013, 62, 1821-1822.	8.2	16
87	Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8⁺ T Cells in Type 1 Diabetes. Science Translational Medicine, 2013, 5, 191ra82.	12.4	149
88	Post-transcriptional control of candidate risk genes for type 1 diabetes by rare genetic variants. Genes and Immunity, 2013, 14, 58-61.	4.1	29
89	Predictive Factors of Allosensitization After Immunosuppressant Withdrawal in Recipients of Long-Term Cultured Islet Cell Grafts. Transplantation, 2013, 96, 162-169.	1.0	9
90	Navigating diabetes-related immune epitope data: re-sources and tools provided by the Immune Epitope Da-tabase (IEDB). Immunome Research, 2013, 9, .	0.1	6

#	Article	IF	Citations
91	Antigen Targets of Type 1 Diabetes Autoimmunity. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007781-a007781.	6.2	171
92	Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. Journal of Experimental Medicine, 2012, 209, 51-60.	8.5	572
93	PS2 - 11. Immune signatures defining graft acceptance in clinical islet transplantation. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 106-106.	0.0	0
94	The contribution of genetic risk factors other than the HLA shared epitope alleles to the genetic variance of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A52.1-A52.	0.9	0
95	CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity. Clinical and Experimental Immunology, 2012, 170, 57-65.	2.6	41
96	The problems and promises of research into human immunology and autoimmune disease. Nature Medicine, 2012, 18, 48-53.	30.7	51
97	Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS. Journal of Clinical Oncology, 2011, 29, 902-908.	1.6	210
98	Diabetogenic T lymphocytes in human Type 1 diabetes. Current Opinion in Immunology, 2011, 23, 746-753.	5.5	79
99	Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. Journal of Autoimmunity, 2011, 37, 151-159.	6.5	66
100	New hope for immune intervention therapy in type 1 diabetes. Lancet, The, 2011, 378, 376-378.	13.7	9
101	PS13 - 66. The type 1 diabetes associated HLA-DQ8-transdimer accommodates a unique islet peptide repertoire. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 135-136.	0.0	0
102	PS13 - 67. Why islet-specific cytotoxic T-cells escape the thymus. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 136-136.	0.0	0
103	Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clinical and Experimental Immunology, 2010, 159, 338-343.	2.6	161
104	Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nature Reviews Immunology, 2010, 10, 145-152.	22.7	59
105	Naturally Arising Human CD4 T-Cells That Recognize Islet Autoantigens and Secrete Interleukin-10 Regulate Proinflammatory T-Cell Responses via Linked Suppression. Diabetes, 2010, 59, 1451-1460.	0.6	96
106	Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cellâ€“Associated Epitopes Using Combinatorial MHC Multimers. Diabetes, 2010, 59, 1721-1730.	0.6	187
107	Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients. Diabetes, 2009, 58, 2267-2276.	0.6	96
108	Accumulation of autoreactive effector T cells and allo-specific regulatory T cells in the pancreas allograft of a type 1 diabetic recipient. Diabetologia, 2009, 52, 494-503.	6.3	44

#	Article	IF	Citations
109	Immunological efficacy of heat shock protein 60 peptide DiaPep277TM therapy in clinical type I diabetes. Clinical and Experimental Immunology, 2008, 152, 488-497.	2.6	88
110	Islet Autoreactive CD8 T-cells in Type 1 Diabetes. Diabetes, 2008, 57, 1156-1156.	0.6	21
111	Immune Markers of Disease and Therapeutic Intervention in Type 1 Diabetes. Novartis Foundation Symposium, 2008, 292, 159-173.	1.1	2
112	Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation. PLoS ONE, 2008, 3, e2435.	2.5	172
113	CTLs are targeted to kill Î² cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. Journal of Clinical Investigation, 2008, 118, 3390-402.	8.2	315
114	Coxsackie B4 virus infection of Î² cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5115-5120.	7.1	521
115	Therapy with the hsp60 peptide DiaPep277â„¢ in C-peptide positive type 1 diabetes patients. Diabetes/Metabolism Research and Reviews, 2007, 23, 269-275.	4.0	77
116	Translational Mini-Review Series on Type 1 Diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes. Clinical and Experimental Immunology, 2007, 148, 1-16.	2.6	233
117	Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17444-17449.	7.1	166
118	Defective Suppressor Function in CD4+CD25+ T-Cells From Patients With Type 1 Diabetes. Diabetes, 2005, 54, 92-99.	0.6	745
119	HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambertâ€“Eaton myasthenic syndrome. Journal of Neuroimmunology, 2005, 159, 230-237.	2.3	80
120	Autoreactive CD8 T cells associated with Â cell destruction in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18425-18430.	7.1	252
121	Detection of Autoreactive T Cells in Type 1 Diabetes Using Coded Autoantigens and an Immunoglobulin-Free Cytokine ELISPOT Assay: Report from the Fourth Immunology of Diabetes Society T Cell Workshop. Annals of the New York Academy of Sciences, 2004, 1037, 10-15.	3.8	38
122	Pro- and anti-inflammatory cytokine production by autoimmune T cells against preproinsulin in HLA-DRB1*04, DQ8 Type 1 diabetes. Diabetologia, 2004, 47, 439-450.	6.3	62
123	Animal models have little to teach us about Type 1 diabetes: 1. In support of this proposal. Diabetologia, 2004, 47, 1650-1656.	6.3	86
124	Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. Journal of Clinical Investigation, 2004, 113, 451-463.	8.2	420
125	The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure. Diabetologia, 2003, 46, 305-321.	6.3	343
126	Molecular mimicry in autoimmune neurological disease after viral infection. Current Medicinal Chemistry, 2003, 10, 1939-43.	2.4	1

#	Article	IF	Citations
127	Modulation of autoimmunity to beta-cell antigens by proteases. Diabetologia, 2002, 45, 686-692.	6.3	20
128	Autoreactive T cells in endocrine/organ-specific autoimmunity: why has progress been so slow?. Seminars in Immunopathology, 2002, 24, 261-271.	4.0	21
129	Molecular Mimicry in Type 1 Diabetes. Annals of the New York Academy of Sciences, 2002, 958, 163-165.	3.8	39
130	Molecular mimicry in type 1 diabetes: immune cross-reactivity between islet autoantigen and human cytomegalovirus but not Coxsackie virus. Annals of the New York Academy of Sciences, 2002, 958, 163-5.	3.8	14
131	Type 1 diabetes: how to resist a fatal attraction. Netherlands Journal of Medicine, 2002, 60, 296-7.	0.5	0
132	Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 3988-3991.	7.1	174
133	Multifocal or generalized tonic dystonia of complex regional pain syndrome: A distinct clinical entity associated with HLA-DR13. Annals of Neurology, 2000, 48, 113-116.	5.3	113
134	T-Cell Reactivity Beta-Cell Antigens in Human Insulin-Dependent (Type 1) Diabetes Mellitus: Implications for Diagnosis and Therapy. Clinical Reviews in Allergy and Immunology, 2000, 19, 265-276.	6.5	3
135	Acute Onset of Type I Diabetes Mellitus after Severe Echovirus 9 Infection: Putative Pathogenic Pathways. Clinical Infectious Diseases, 2000, 31, 1025-1031.	5.8	88
136	HLA-DRB1*0403 is associated with dominant protection against IDDM in the general Dutch population and subjects with high-risk DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201 genotype. Tissue Antigens, 1999, 54, 88-90.	1.0	19
137	Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes, 1999, 48, 484-490.	0.6	183
138	Quantitative determination of TCR cross-reactivity using peptide libraries and protein databases. European Journal of Immunology, 1999, 29, 2385-2391.	2.9	31
139	Autoreactive T cell Responses in Insulin-dependent (Type 1) Diabetes Mellitus. Report of the First International Workshop for Standardization of T cell assays. Journal of Autoimmunity, 1999, 13, 267-282.	6.5	121
140	Quantitative determination of TCR cross-reactivity using peptide libraries and protein databases. European Journal of Immunology, 1999, 29, 2385-2391.	2.9	1
141	HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. European Journal of Immunology, 1996, 26, 1285-1289.	2.9	67
142	T-Cell Reactivity to Î²-Cell Membrane Antigens Associated With Î²-Cell Destruction in IDDM. Diabetes, 1995, 44, 278-283.	0.6	87
143	Soluble forms of intercellular adhesion molecule-1 in insulin-dependent diabetes mellitus. Lancet, The, 1994, 343, 1590-1593.	13.7	89
144	Â-Cell Antigen-Specific Lysis of Macrophages by CD4 T-Cell Clones From Newly Diagnosed IDDM Patient: A Putative Mechanism of T-Cell-Mediated Autoimmune Islet Cell Destruction. Diabetes, 1992, 41, 1380-1384.	0.6	27

#	Article	IF	Citations
145	T-cell reactivity to 38 kD insulin-secretory-granule protein in patients with recent-onset type 1 diabetes. Lancet, The, 1991, 337, 1439-1441.	13.7	124
146	T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. Nature, 1990, 345, 632-634.	27.8	191
147	Human T cell clones with specificity for insulinoma cell antigens. European Journal of Immunology, 1989, 19, 213-216.	2.9	40
148	From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes. Frontiers in Medicine, 0, 9, .	2.6	13